Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress

Market Focus

3小時前

On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.

On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.

Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1112377946"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112377946\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112377946?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-04 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112377946","market":"us","top_or_hot":-1,"title":"Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress","media":"Market Focus","content":"<p><p>On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜GENSCRIPT BIO Rises 5.15% in Regular Trading, CARVYKTI Q2 Sales Surge Nearly 50% YoY Combined with Pipeline Progress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-08-04 09:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.</p><p>On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.</p><p>Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1112377946","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112377946","pubTimestamp":1785807528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.On the news front, the company's associate Legend Biotech previously...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"走势提醒|金斯瑞生物常规交易上涨 5.15%，CARVYKTI 第二季度销售额同比飙升近 50%，加上管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"On August 4, GENSCRIPT BIO rose 5.15% in regular trading, trading at HKD 17.67 per share, with turnover of HKD 106 million.On the news front, the company's associate Legend Biotech previously disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing a nearly 50% year-over-year increase and sustaining strong growth momentum. The sales figure was provided by partner Janssen Biotech under their collaboration and license agreement signed in December 2017.Additionally, Legend Biotech's investigational in vivo CD19/CD20 dual-target CAR-T therapy LB2501 achieved a 100% objective response rate in a Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma patients, with no dose-limiting toxicities observed. The combination of robust commercial performance and positive pipeline advancement continues to support investor sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}